Educational Guide

Growth Hormone Secretagogues: Complete Overview

A comprehensive guide to growth hormone secretagogues including GHRPs, GHRH analogs, and their mechanisms. Understanding the GH-releasing peptide landscape.

Growth Hormone16 min readDecember 21, 2025

Introduction to Growth Hormone Secretagogues

Growth hormone secretagogues (GHS) represent a class of compounds that stimulate the body's natural growth hormone (GH) production rather than providing exogenous GH directly. This approach has significant research interest because it may better preserve natural regulatory mechanisms while still augmenting GH levels.

This comprehensive overview examines the major classes of secretagogues, their mechanisms, and research applications.

Growth Hormone Physiology

Understanding Natural GH Release

GH is released from the anterior pituitary in a pulsatile pattern regulated by:

Stimulating Factors:

  • GHRH (Growth Hormone Releasing Hormone) from hypothalamus
  • Ghrelin from stomach
  • Sleep (GH peaks during slow-wave sleep)
  • Exercise
  • Fasting
  • Low blood glucose

Inhibiting Factors:

  • Somatostatin from hypothalamus
  • IGF-1 (negative feedback)
  • High blood glucose
  • Free fatty acids
  • Age (progressive decline)

The Somatopause

GH secretion declines with age:

  • Peaks in adolescence
  • Decreases ~14% per decade after age 30
  • By age 60, levels may be 20-30% of young adult
  • Contributes to age-related body composition changes

This decline drives interest in secretagogues for aging research.

Classes of GH Secretagogues

GHRH Analogs

Mechanism:

  • Bind to GHRH receptors on pituitary somatotrophs
  • Stimulate GH synthesis and release
  • Require somatostatin to be low for maximal effect

Key Compounds:

Sermorelin:

  • GHRH(1-29) - first 29 amino acids of GHRH
  • Short half-life (~10-20 minutes)
  • Requires frequent administration
  • Previously FDA-approved (discontinued)

CJC-1295 (no DAC / Mod GRF 1-29):

  • Modified GHRH(1-29)
  • Increased stability
  • Half-life ~30 minutes
  • Common research compound

CJC-1295 with DAC:

  • Drug Affinity Complex enables albumin binding
  • Extended half-life (~8 days)
  • Less pulsatile release pattern
  • Once or twice weekly administration

Tesamorelin:

  • GHRH analog with N-terminal modification
  • FDA-approved for HIV-lipodystrophy
  • Best-studied GHRH analog
  • Limited availability for general research

Growth Hormone Releasing Peptides (GHRPs)

Mechanism:

  • Bind to ghrelin receptor (GHS-R1a)
  • Amplify GH pulse amplitude
  • Suppress somatostatin
  • Synergize with GHRH

Key Compounds:

GHRP-6:

  • First widely used GHRP
  • Strong GH release
  • Significant appetite stimulation (ghrelin effect)
  • May increase cortisol and prolactin
  • See our GHRP-2 vs GHRP-6 comparison

GHRP-2:

  • Strong GH release
  • Less appetite stimulation than GHRP-6
  • Some cortisol and prolactin elevation
  • Popular research compound

Ipamorelin:

  • Most selective GHRP
  • Minimal cortisol or prolactin increase
  • Minimal appetite stimulation
  • "Cleanest" GH release
  • Very popular in research

Hexarelin:

  • Potent GH release
  • May cause more desensitization
  • Limited availability
  • Less commonly used

Comparison Table

CompoundGH ReleaseAppetiteCortisolProlactinSelectivity
GHRP-6StrongHighModerateModerateLow
GHRP-2StrongModerateLow-ModLow-ModModerate
IpamorelinModerateMinimalMinimalMinimalHigh
HexarelinVery StrongModerateModerateModerateLow

Synergy: Combining GHRH + GHRP

The Rationale

Combining GHRH analogs with GHRPs produces synergistic effects:

Why It Works:

  1. GHRP suppresses somatostatin
  2. Creates optimal window for GHRH action
  3. GHRH stimulates GH synthesis and release
  4. GHRP amplifies pulse amplitude
  5. Combined effect exceeds sum of individual effects

Common Combinations

CJC-1295 + Ipamorelin:

  • Most popular combination
  • GHRH + selective GHRP
  • Minimal side effects
  • Well-researched synergy

CJC-1295 + GHRP-2:

  • Stronger GH release
  • More side effects
  • Used when maximal stimulation desired

Research Evidence

Studies demonstrate:

  • Combined administration produces greater GH release
  • Synergy is more than additive
  • Effect is consistent across protocols
  • May better mimic physiological patterns

Research Applications

Body Composition

GH Effects on Composition:

  • Lipolysis (fat breakdown)
  • Protein synthesis support
  • Lean mass effects
  • Regional fat distribution

Secretagogue Research:

  • Studies on fat reduction
  • Lean mass preservation
  • Metabolic effects
  • Comparison with direct GH

Sleep and Recovery

GH and Sleep:

  • Natural GH peaks during slow-wave sleep
  • Secretagogues may enhance this

Research Areas:

  • Sleep quality improvements
  • Recovery optimization
  • Training adaptations
  • Overtraining prevention

Anti-Aging

Addressing Somatopause:

  • Restoring youthful GH levels
  • Body composition normalization
  • Skin and connective tissue
  • Cognitive effects

See our anti-aging guide for 50+.

Clinical Applications

Established Uses:

  • Growth hormone deficiency diagnosis
  • Tesamorelin for HIV-lipodystrophy
  • Research in various conditions

Investigational:

  • Obesity and metabolic syndrome
  • Sarcopenia (muscle loss with aging)
  • Frailty in elderly
  • Wound healing

Administration Considerations

Timing

Optimal Timing:

  • Fasted state (2-3 hours after eating)
  • Before bed (aligns with natural peak)
  • Pre-exercise (some protocols)
  • 30-60 minutes before eating

Why Fasting Matters:

  • Glucose and fatty acids suppress GH release
  • Fasting optimizes response
  • Carbohydrates particularly blunting

See our timing and dosing guide.

Frequency

Short Half-Life Compounds (most):

  • 2-3 times daily
  • Common: morning, pre-workout, pre-bed
  • Consistency important

CJC-1295 with DAC:

  • 1-2 times weekly
  • Sustained elevation rather than pulses
  • Different physiological pattern

Reconstitution and Storage

All secretagogues require:

  • Proper reconstitution with bacteriostatic water
  • Refrigerated storage after reconstitution
  • Protection from light
  • Sterile technique

See our reconstitution guide and storage guide.

Side Effects and Considerations

Common Effects

Generally Mild:

  • Water retention (early)
  • Tingling/numbness (sign of elevated GH)
  • Injection site reactions
  • Head rush (transient, with some compounds)

Compound-Specific

GHRP-6:

  • Intense hunger (can be significant)
  • Cortisol elevation

GHRP-2:

  • Moderate hunger increase
  • Some cortisol effect

Ipamorelin:

  • Minimal side effects
  • Most well-tolerated

Longer-Term Considerations

Pituitary Concerns:

  • Desensitization possible (especially Hexarelin)
  • Cycling may be prudent
  • Less concern than with direct GH

IGF-1 Elevation:

  • GH increases IGF-1
  • Theoretical concerns about cell proliferation
  • Monitor with blood tests
  • Context-dependent risk assessment

Quality and Sourcing

Importance

As research compounds, quality varies:

  • Purity affects response
  • Contamination risks
  • Proper identification essential

Verification

  • Third-party testing certificates
  • Mass spectrometry verification
  • HPLC purity data
  • See supplier guide

Conclusion

Growth hormone secretagogues offer research tools for studying GH physiology and its effects on various biological processes. The combination of GHRH analogs (like CJC-1295) with selective GHRPs (like Ipamorelin) provides a synergistic approach that may better preserve natural regulatory mechanisms than direct GH administration.

Key principles:

  1. Two pathways - GHRH and ghrelin receptor
  2. Synergy - combinations more effective than singles
  3. Selectivity - Ipamorelin minimizes side effects
  4. Timing - fasted administration optimizes response
  5. Quality - essential for meaningful research

Understanding these compounds provides a foundation for research into aging, body composition, recovery, and various clinical applications.

Related Resources:

References

Teichman SL, et al.. (2006). Prolonged stimulation of GH by CJC-1295. J Clin Endocrinol Metab.

Raun K, et al.. (1998). Ipamorelin, the first selective GHS. Eur J Endocrinol.

Bowers CY. (1998). Growth hormone-releasing peptide. Cell Mol Life Sci.

Topics

Growth HormoneGHRPIpamorelin
DMR

Dr. Michael Roberts

MD, PhDResearching Peptides Medical Advisor

Dr. Roberts provides medical oversight and ensures content accuracy for clinical research topics. With over 15 years of experience in endocrinology research, he brings valuable expertise to our editorial process.